A recombinant full-length VP2-2b-based ELISA for evaluating immunoprotection against canine parvovirus-2: Expression, development and validation | Synapse
March 3, 2026
A recombinant full-length VP2-2b-based ELISA for evaluating immunoprotection against canine parvovirus-2: Expression, development and validation
Key Points
The developed ELISA effectively evaluates immunoprotection against canine parvovirus-2, indicating potential for improved veterinary care.
Validation of the recombinant VP2-2b protein demonstrated a strong antibody response in canine subjects.
Assessment involved both expression and development of the ELISA, ensuring reliable detection of immune responses.
Successful validation supports the ELISA's use in monitoring vaccination efficacy, highlighting its relevance in veterinary diagnostics.